{
  "schemaVersion": 2,
  "eyebrow": "Hepatology",
  "title": "Wilson Disease",
  "summary": "Diagnose Wilson disease by integrating copper studies, ophthalmologic and neurologic findings, and ATP7B testing when results are equivocal; then select lifelong chelation or zinc according to phenotype, hepatic severity, tolerance, and adherence risk.",
  "seoDescription": "Point-of-care diagnosis, treatment selection, transplant indications, pregnancy management, and monitoring for Wilson disease.",
  "clinicalQuestion": "How should physicians confirm, treat, and monitor Wilson disease across hepatic, neurologic, and presymptomatic presentations?",
  "specialty": "Hepatology",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "Wilson disease",
    "ATP7B",
    "ceruloplasmin",
    "24-hour urine copper",
    "trientine",
    "penicillamine",
    "zinc acetate",
    "acute liver failure"
  ],
  "keyTakeaways": [
    "Do not use a single copper test to exclude Wilson disease; integrate clinical findings, ceruloplasmin, 24-hour urinary copper, ophthalmologic assessment, and ATP7B testing when the phenotype remains uncertain. [15][17][18]",
    "Ceruloplasmin below 10 mg/dL and 24-hour urinary copper excretion above 100 micrograms favor Wilson disease, but acute hepatitis can limit urinary copper interpretation. [9][15]",
    "Symptomatic disease generally requires initial copper removal with penicillamine or trientine; zinc is principally a maintenance option after chelation and requires close adherence and biochemical monitoring. [1][11][12][19]",
    "Refer acute liver failure and decompensated cirrhosis promptly for liver transplant evaluation; transplantation is generally reserved for acute liver failure or decompensated cirrhosis and corrects the hepatic metabolic defect. [14][20]",
    "Medical therapy is lifelong. Treatment interruption can precipitate neurologic or psychiatric manifestations or acute liver failure. [12][23]"
  ],
  "sections": [
    {
      "id": "recognize-urgent-phenotypes",
      "eyebrow": "Triage",
      "heading": "Identify phenotypes that require urgent transplant-centered management",
      "intro": "Separate acute liver failure and decompensation from stable hepatic or neurologic disease before choosing outpatient decoppering therapy.",
      "paragraphs": [
        "In suspected Wilson disease with acute liver failure, obtain copper-directed testing promptly but do not delay transfer to a liver-transplant center while awaiting ceruloplasmin, 24-hour urinary copper, or hepatic copper results; these markers may be difficult to obtain or interpret in fulminant disease. Liver transplantation is typically necessary in fulminant hepatic failure and is generally reserved for acute liver failure or decompensated cirrhosis. [5][14][20]",
        "For decompensated cirrhosis without acute liver failure, involve transplant hepatology while initiating disease-specific therapy. AASLD- and ESPGHAN-aligned guidance has proposed initial chelation plus zinc in decompensated cirrhosis, whereas standard management of symptomatic disease otherwise centers on chelation with penicillamine or trientine. [19]",
        "Obtain a detailed neurologic examination in every patient with neurologic signs or symptoms and refer to a neurologist or movement-disorder specialist for a comprehensive assessment. Baseline neurologic characterization is necessary because neurologic worsening can occur after therapy initiation, particularly with penicillamine. [16][12][19]"
      ],
      "bullets": [
        "Acute liver failure: immediate transplant-center referral; copper test results should not postpone escalation. [5][14]",
        "Decompensated cirrhosis: coordinate chelation strategy with hepatology and transplant evaluation. [19][20]",
        "Neurologic phenotype: document baseline speech, movement, psychiatric, and functional findings before treatment changes. [1][16]"
      ],
      "subsections": [],
      "table": {
        "caption": "Initial disposition by clinically actionable Wilson disease presentation. [5][14][16][19][20]",
        "columns": [
          "Presentation",
          "Immediate action",
          "Treatment implication"
        ],
        "rows": [
          [
            "Acute liver failure",
            "Transfer urgently to a liver-transplant center; obtain diagnostic copper studies without delaying escalation. [5][14]",
            "Transplantation is typically necessary in fulminant hepatic failure. [14]"
          ],
          [
            "Decompensated cirrhosis",
            "Engage transplant hepatology and begin disease-specific therapy. [19][20]",
            "Chelation plus zinc is proposed by AASLD and ESPGHAN as initial therapy in this subgroup. [19]"
          ],
          [
            "Neurologic or psychiatric manifestations",
            "Perform comprehensive neurologic evaluation and establish baseline deficits. [16]",
            "Chelator selection requires attention to risk of neurologic deterioration after treatment initiation. [12][19]"
          ],
          [
            "Presymptomatic or stable disease",
            "Confirm diagnosis and start lifelong anti-copper treatment rather than observation alone. [12][23]",
            "A chelator or zinc may be used in patients without organ damage, depending on guideline approach and patient factors. [19]"
          ]
        ]
      }
    },
    {
      "id": "confirm-diagnosis",
      "eyebrow": "Diagnosis",
      "heading": "Confirm Wilson disease with a composite copper and genetic assessment",
      "intro": "Use concordant clinical, biochemical, ophthalmologic, and molecular evidence rather than a single screening marker.",
      "paragraphs": [
        "In a patient with unexplained liver disease, neurologic disease, psychiatric manifestations, Coombs-negative hemolytic anemia, or a compatible family history, obtain serum ceruloplasmin and a 24-hour urine copper collection as initial copper studies. Ceruloplasmin below 10 mg/dL and urinary copper above 100 micrograms per 24 hours favor Wilson disease. [9][22]",
        "Interpret copper studies in clinical context. Urinary copper testing is specifically limited during acute hepatitis, and fulminant presentations may not permit timely acquisition of ceruloplasmin, 24-hour urine copper, or hepatic copper results. Do not use a delayed or discordant result in that setting to defer lifesaving liver-transplant evaluation. [5][15][22]",
        "Request slit-lamp examination for Kayser-Fleischer rings when Wilson disease is suspected, particularly in neurologic presentations. When clinical and biochemical testing is ambiguous, incorporate ATP7B molecular testing and other components of the Leipzig diagnostic index, which combines clinical, biochemical, and molecular findings; a Leipzig score of at least 4 is used as a diagnostic threshold in clinical trial confirmation criteria. [17][18][22][24]",
        "Screen first-degree relatives with clinical and genetic testing. Family-directed testing enables diagnosis before irreversible hepatic or neurologic injury and supports initiation of lifelong treatment in affected relatives. [15][22][23]"
      ],
      "bullets": [
        "Initial tests: serum ceruloplasmin plus 24-hour urinary copper. [9][22]",
        "Diagnostic pattern favoring Wilson disease: ceruloplasmin less than 10 mg/dL plus urinary copper greater than 100 micrograms per 24 hours. [9]",
        "If results are equivocal: add slit-lamp examination, ATP7B testing, and composite Leipzig scoring. [17][18][22][24]",
        "If acute liver failure is present: prioritize transplant referral over completion of diagnostic testing. [5][14]"
      ],
      "subsections": [
        {
          "heading": "When diagnostic results conflict",
          "paragraphs": [
            "Discordant copper studies should trigger a structured reassessment rather than empiric discontinuation of evaluation: verify the timed urine collection, review the hepatic versus neurologic phenotype, obtain ophthalmologic findings, and pursue ATP7B testing. The AASLD diagnostic pathway emphasizes additional approaches when clinical and biochemical evaluations are ambiguous, whereas European guidance uses the Leipzig composite score. [15][17][18]"
          ],
          "bullets": []
        }
      ],
      "table": {
        "caption": "Diagnostic elements used to establish Wilson disease. [9][15][17][18][22][24]",
        "columns": [
          "Test or finding",
          "Decision threshold or role",
          "Interpretation and next action"
        ],
        "rows": [
          [
            "Serum ceruloplasmin",
            "Less than 10 mg/dL favors Wilson disease. [9]",
            "Combine with urinary copper and phenotype; do not treat as a stand-alone exclusion test. [15][17]"
          ],
          [
            "24-hour urinary copper",
            "Greater than 100 micrograms per 24 hours favors Wilson disease. [9]",
            "Interpret cautiously during acute hepatitis; use other diagnostic elements when results are unreliable or delayed. [5][15]"
          ],
          [
            "Kayser-Fleischer rings",
            "Included among historical and composite diagnostic findings. [22][24]",
            "Obtain slit-lamp examination as part of the integrated assessment. [22][24]"
          ],
          [
            "ATP7B molecular testing",
            "Used when clinical and biochemical evidence is ambiguous and for family evaluation. [15][17][18]",
            "Supports confirmation and cascade testing of first-degree relatives. [15][22]"
          ],
          [
            "Leipzig score",
            "Score of at least 4 is used for diagnostic confirmation in trial criteria. [24]",
            "Useful composite framework when no single finding is definitive. [17][24]"
          ]
        ]
      }
    },
    {
      "id": "select-lifelong-therapy",
      "eyebrow": "Treatment",
      "heading": "Choose chelation or zinc according to phenotype and treatment phase",
      "intro": "Treatment has an initial decoppering phase followed by maintenance to prevent copper reaccumulation.",
      "paragraphs": [
        "Initiate lifelong medical therapy in newly diagnosed Wilson disease. Initial treatment aims to remove or detoxify accumulated tissue copper and typically uses a chelator; maintenance prevents reaccumulation with continued chelation at a reduced dose or zinc salts. Discontinuation can lead to neurologic or psychiatric symptoms or acute liver failure. [12][23]",
        "Use penicillamine or trientine as initial therapy for symptomatic patients. Penicillamine increases urinary copper excretion but has substantial long-term tolerability limitations, with approximately 30% of patients unable to tolerate it because of adverse effects; some patients with neurologic manifestations develop worsening that may be irreversible. Trientine is a reasonable primary alternative because it has a lower incidence of adverse effects, although neurologic deterioration has rarely been reported after initiation. [12][13][19]",
        "For pediatric initial penicillamine treatment, the AASLD-referenced dose is 20 mg/kg/day. Do not extrapolate this pediatric dose to adults without product-specific prescribing information and specialist oversight. [23]",
        "Use zinc as maintenance therapy after initial chelation in patients with Wilson disease; FDA labeling for zinc acetate specifies this indication. Zinc blocks dietary copper absorption and increases metallothionein. Zinc may also be selected as first-line therapy in presymptomatic patients without organ damage under AASLD and EASL approaches, while ESPGHAN favors zinc monotherapy in that setting. [1][12][19]",
        "Avoid assuming that zinc is interchangeable with chelation in symptomatic hepatic disease. Long-term observational data found treatment discontinuation from failure, transplantation, or death in 18 of 88 zinc-treated patients and suggested chelators may better prevent hepatic deterioration; identify nonresponse early by clinical and urinary copper monitoring and assess adherence before declaring pharmacologic failure. [11]"
      ],
      "bullets": [
        "Symptomatic hepatic, neurologic, or psychiatric disease: start a chelator unless the clinical context dictates an alternative approach. [12][19]",
        "Penicillamine: consider neurologic-worsening and tolerability risk; approximately 30% have long-term intolerance. [12]",
        "Trientine: reasonable alternative or primary chelator when penicillamine intolerance or adverse-effect risk is a concern. [12][13]",
        "Zinc acetate: FDA-indicated for maintenance after initial chelation; monitor closely for efficacy, adherence, and copper deficiency. [1][11]",
        "Presymptomatic disease: do not defer treatment; chelator or zinc selection varies across guideline frameworks. [19][23]"
      ],
      "subsections": [
        {
          "heading": "Diet and exposure reduction",
          "paragraphs": [
            "Recommend a low-copper diet, particularly during the first treatment year. Review preventable copper exposure from well water, plumbing systems, and cookware; advise avoidance of alcohol and hepatotoxic substances in patients with liver involvement. [19][22]"
          ],
          "bullets": []
        },
        {
          "heading": "Pregnancy",
          "paragraphs": [
            "Continue anti-copper therapy during pregnancy. For patients receiving chelation, reduce the dose by approximately 50% and increase monitoring before conception when possible and during pregnancy; zinc dosing does not require adjustment. Zinc acetate labeling recommends that women receiving zinc not breastfeed because zinc-induced copper deficiency may occur in the nursing infant. [12][1]"
          ],
          "bullets": []
        }
      ],
      "table": {
        "caption": "Treatment selection and major tradeoffs in Wilson disease. [1][11][12][13][19][23]",
        "columns": [
          "Clinical situation",
          "Preferred treatment approach",
          "Key tradeoff or monitoring priority"
        ],
        "rows": [
          [
            "Symptomatic Wilson disease",
            "Initial chelation with penicillamine or trientine. [12][19]",
            "Track clinical response and urinary copper; assess for treatment-emergent neurologic deterioration. [12][23]"
          ],
          [
            "Penicillamine intolerance or adverse-effect concern",
            "Use trientine as an alternative and reasonable primary chelator. [12][13]",
            "Monitor for iron deficiency, sideroblastic anemia, dermatitis, colitis, and rare neurologic deterioration. [13]"
          ],
          [
            "Maintenance after initial chelation",
            "Continue chelation at a maintenance dose or use zinc; zinc acetate is FDA-indicated for maintenance. [1][12]",
            "Zinc effectiveness depends on dose, tolerability, and adherence; monitor for nonresponse. [11]"
          ],
          [
            "Presymptomatic disease without organ damage",
            "Use a chelator or zinc under AASLD/EASL approaches; ESPGHAN favors zinc monotherapy. [19]",
            "Do not observe untreated; therapy is lifelong. [12][23]"
          ],
          [
            "Decompensated cirrhosis",
            "Chelation plus zinc is proposed by AASLD and ESPGHAN as initial therapy while transplant candidacy is assessed. [19]",
            "Escalate promptly to transplant hepatology. [20]"
          ]
        ]
      }
    },
    {
      "id": "monitor-response-and-toxicity",
      "eyebrow": "Follow-up",
      "heading": "Monitor clinical response, copper balance, adherence, and drug toxicity",
      "intro": "Interpret laboratory trends with symptoms and treatment phase rather than relying on a single target.",
      "paragraphs": [
        "At follow-up, assess hepatic status, neurologic and psychiatric manifestations, and adherence alongside copper indices and hematologic parameters. Routine monitoring should include biochemical testing and clinical evaluation; regular liver tests, copper indices, and hematologic parameters help detect adverse effects and treatment failure. [2][17]",
        "During chelation, measure 24-hour urinary copper excretion. Excretion is highest soon after therapy begins and may exceed 1,000 to 2,000 micrograms daily; during maintenance, approximately 200 to 500 micrograms daily is expected. In a patient previously excreting 200 to 500 micrograms daily, a value above 500 micrograms daily suggests either nonadherence to penicillamine or increased copper intake. [23]",
        "For zinc acetate, monitor existing Wilson disease manifestations, 24-hour urinary copper, neuropsychiatric status including speech, liver tests including bilirubin and aminotransferases, and hematologic indices. Extended zinc exposure can cause copper deficiency with anemia, granulocytopenia, leukopenia, neutropenia, pancytopenia, thrombocytopenia, or myeloneuropathy. [1]",
        "When clinical deterioration or an unfavorable copper trend occurs, first verify medication access, dosing schedule, and adherence before changing agents. Zinc failure may reflect inadequate dose, intolerance, or nonadherence, but persistent hepatic deterioration warrants reassessment for chelation and transplant-center involvement when cirrhosis is decompensated. [11][19][20]"
      ],
      "bullets": [
        "Chelator monitoring: clinical response, liver biochemistries, hematologic parameters, and 24-hour urinary copper. [2][17][23]",
        "Early chelation: urinary copper may exceed 1,000 to 2,000 micrograms daily. [23]",
        "Maintenance chelation: urinary copper is typically about 200 to 500 micrograms daily. [23]",
        "Zinc: monitor for both undertreatment and copper-deficiency cytopenias or myeloneuropathy. [1][11]",
        "Neurologic disease: repeat focused neurologic and speech assessment to distinguish progression from treatment-associated worsening. [1][12][16]"
      ],
      "subsections": [],
      "table": {
        "caption": "Monitoring signals that should alter management. [1][2][11][17][23]",
        "columns": [
          "Treatment context",
          "Monitoring signal",
          "Interpretation and action"
        ],
        "rows": [
          [
            "Early chelation",
            "24-hour urinary copper may exceed 1,000 to 2,000 micrograms daily. [23]",
            "This may occur immediately after treatment initiation; interpret with treatment phase and clinical response. [23]"
          ],
          [
            "Maintenance chelation",
            "24-hour urinary copper approximately 200 to 500 micrograms daily. [23]",
            "If previously in this range, a value above 500 micrograms daily suggests nonadherence or increased copper intake. [23]"
          ],
          [
            "Zinc therapy",
            "Worsening liver, neurologic, or psychiatric findings or unfavorable urinary copper trend. [1][11]",
            "Review dose, administration, and adherence promptly; consider treatment failure if abnormalities persist. [11]"
          ],
          [
            "Long-term zinc exposure",
            "Cytopenias or myeloneuropathy. [1]",
            "Evaluate for zinc-induced copper deficiency and revise treatment. [1]"
          ],
          [
            "Any anti-copper therapy",
            "New neurologic findings, hepatic biochemical deterioration, or hematologic abnormalities. [2][12][17]",
            "Assess treatment toxicity, adherence, copper control, and need for specialty escalation. [2][17]"
          ]
        ]
      }
    },
    {
      "id": "prevent-family-morbidity",
      "eyebrow": "Prevention",
      "heading": "Prevent irreversible injury through family testing and durable adherence",
      "intro": "The highest-yield preventive actions are cascade testing and prevention of treatment interruption.",
      "paragraphs": [
        "Test first-degree relatives using clinical and genetic evaluation, then initiate treatment in those diagnosed before organ damage develops. Guideline approaches differ in the exact screening modality, but AASLD and ESPGHAN include clinical and genetic testing for first-degree relatives. [15][22]",
        "Build adherence assessment into every visit because multiple daily dosing, tolerability, and treatment burden are major limitations of lifelong therapy. For zinc-treated patients, adherence is especially important because efficacy depends on appropriate dosage, tolerability, and compliance; unexplained biochemical or clinical worsening should prompt a medication-use review before labeling treatment failure. [11][18]"
      ],
      "bullets": [
        "Cascade-test first-degree relatives rather than waiting for symptoms. [15][22]",
        "Treat diagnosed relatives lifelong, including those without established organ damage. [19][23]",
        "At each visit, ask specifically about missed doses, formulation changes, adverse effects, copper exposure, and pregnancy plans. [1][11][12][22]"
      ],
      "subsections": [],
      "table": {
        "caption": "Preventive actions that reduce Wilson disease morbidity. [11][12][15][19][22][23]",
        "columns": [
          "Action",
          "Who needs it",
          "Clinical purpose"
        ],
        "rows": [
          [
            "Clinical and genetic testing",
            "First-degree relatives. [15][22]",
            "Identifies affected relatives before hepatic or neurologic injury. [22][23]"
          ],
          [
            "Lifelong anti-copper therapy",
            "All newly diagnosed patients, including presymptomatic disease. [19][23]",
            "Prevents copper reaccumulation and avoids consequences of treatment interruption. [12]"
          ],
          [
            "Low-copper diet and exposure review",
            "All patients, especially during the first treatment year. [19][22]",
            "Reduces dietary and environmental copper exposure. [19][22]"
          ],
          [
            "Pregnancy-specific medication plan",
            "Patients planning pregnancy or pregnant. [12]",
            "Prevents treatment interruption while reducing chelator exposure through dose adjustment. [12]"
          ]
        ]
      }
    }
  ],
  "faq": [],
  "references": [
    {
      "number": 1,
      "title": "GALZIN® (Zinc Acetate) Capsules",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a0c72bff-20f3-4241-b966-34a95178d1a3&type=display",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov"
    },
    {
      "number": 2,
      "title": "Clinical Management of Wilson's Disease",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/nature-index/topics/l4/clinical-management-of-wilson-s-disease",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 3,
      "title": "Liver diseases: epidemiology, causes, trends and predictions",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41392-024-02072-z",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 4,
      "title": "binding properties of de-coppering drugs for the treatment ...",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41598-018-19873-2",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 5,
      "title": "Is it possible to diagnose fulminant Wilson's disease with ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1111/liv.14263",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 6,
      "title": "Wilson's Disease: Diagnosis of Wilson's ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1155/2020/7650170",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 7,
      "title": "The dilemma to diagnose Wilson disease by genetic ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/eci.13147",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 8,
      "title": "Diagnosis and Outcomes of Late‐Onset Wilson's Disease",
      "detail": "movementdisorders.onlinelibrary.wiley.com",
      "url": "https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.29292",
      "authors": "movementdisorders.onlinelibrary.wiley.com",
      "host": "movementdisorders.onlinelibrary.wiley.com"
    },
    {
      "number": 9,
      "title": "Minimal Criteria to Screen for Wilson Disease: A Delphi ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1155/ijh/5525442",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 10,
      "title": "evaluation of the diagnostic criteria for Wilson disease in ...",
      "detail": "aasldpubs.onlinelibrary.wiley.com",
      "url": "https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.23910",
      "authors": "aasldpubs.onlinelibrary.wiley.com",
      "host": "aasldpubs.onlinelibrary.wiley.com"
    },
    {
      "number": 11,
      "title": "Zinc Maintenance Therapy for Wilson Disease: A... : Hepatology Communications",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/hepcomm/fulltext/2019/08000/zinc_maintenance_therapy_for_wilson_disease__a.14.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 12,
      "title": "Wilson disease: Clinical manifestations,... : Clinical Liver Disease",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/cld/pdf/10.1002/cld.349~wilson-disease-clinical-manifestations-diagnosis-and",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 13,
      "title": "Prospective Study to Assess Long‐Term Outcomes of... : JGH Open",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/02045866-202503000-00004",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 14,
      "title": "Wilson Disease | Continuum",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/continuum/fulltext/2016/08000/wilson_disease.16.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 15,
      "title": "Clinical practice guidelines in Wilson disease - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6531645",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 16,
      "title": "Comparative management practices of Wilson disease in Californian and Italian providers - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12487098",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 17,
      "title": "Wilson Disease - GeneReviews® - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK1512",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 18,
      "title": "Wilson disease: a summary of the updated AASLD Practice Guidance",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10187853",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 19,
      "title": "Treatment patterns in a real-world cohort of patients with Wilson disease in the United States - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12952460",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 20,
      "title": "Clinical Review - Trientine Hydrochloride (MAR-Trientine) - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK595409",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 21,
      "title": "Clinical practice guidelines in Wilson disease - PubMed - NIH",
      "detail": "pubmed.ncbi.nlm.nih.gov",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31179302",
      "authors": "pubmed.ncbi.nlm.nih.gov",
      "host": "pubmed.ncbi.nlm.nih.gov"
    },
    {
      "number": 22,
      "title": "Wilson Disease - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK441990",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 23,
      "title": "Penicillamine - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK513316",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 24,
      "title": "PROTOCOL TITLE PAGE",
      "detail": "cdn.clinicaltrials.gov",
      "url": "https://cdn.clinicaltrials.gov/large-docs/31/NCT04422431/Prot_000.pdf",
      "authors": "cdn.clinicaltrials.gov",
      "host": "cdn.clinicaltrials.gov"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "GALZIN® (Zinc Acetate) Capsules",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a0c72bff-20f3-4241-b966-34a95178d1a3&type=display",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov",
      "snippet": "# INDICATIONS AND USAGE\n\nZinc acetate therapy is indicated for maintenance treatment of patients with Wilson’s disease who have been initially treated with a chelating agent (See PRECAUTIONS: Monitoring Patients).\n\n# CONTRAINDICATIONS\n\nZinc Acetate Capsules are contraindicated in patients with known",
      "score": 0.49802306
    },
    {
      "number": 2,
      "title": "Clinical Management of Wilson's Disease",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/nature-index/topics/l4/clinical-management-of-wilson-s-disease",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Regular monitoring of liver function, copper indices and haematological parameters is essential to detect adverse effects and to ensure adherence.",
      "score": 0.5299209
    },
    {
      "number": 3,
      "title": "Liver diseases: epidemiology, causes, trends and predictions",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41392-024-02072-z",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Article \n     Google Scholar\n456. Konkwo, C., Chowdhury, S. & Vilarinho, S. Genetics of liver disease in adults. Hepatol. Commun. 8 (2024).\n457. Tarnacka, B., Szeszkowski, W., Golebiowski, M. & Czlonkowska, A. MR spectroscopy in monitoring the treatment of Wilson’s disease patients. Mov. Disord. 23,",
      "score": 0.50476116
    },
    {
      "number": 4,
      "title": "binding properties of de-coppering drugs for the treatment ...",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41598-018-19873-2",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "by J Smirnova · 2018 · Cited by 100 — Wilson disease is treatable, primarily by copper-chelation therapy, D-penicillamine, trientine, D-penicillamine (PA), the first orally",
      "score": 0.38964
    },
    {
      "number": 5,
      "title": "Is it possible to diagnose fulminant Wilson's disease with ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1111/liv.14263",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "1 However, it is almost impossible to obtain diagnostic marker results including ceruloplasmin, 24-hour urinary copper and hepatic copper",
      "score": 0.64719695
    },
    {
      "number": 6,
      "title": "Wilson's Disease: Diagnosis of Wilson's ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1155/2020/7650170",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "Serum ceruloplasmin concentration was reduced (<10 mg/dl), and 24 hr urinary copper excretion was increased (142.2 μg/24 hrs). In sum, the",
      "score": 0.6122407
    },
    {
      "number": 7,
      "title": "The dilemma to diagnose Wilson disease by genetic ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/eci.13147",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "by AF Stättermayer · 2019 · Cited by 62 — Diagnosis is based on the presence of these clinical symptoms and laboratory findings (ceruloplasmin, 24 hours urinary copper excretion,",
      "score": 0.5749443
    },
    {
      "number": 8,
      "title": "Diagnosis and Outcomes of Late‐Onset Wilson's Disease",
      "detail": "movementdisorders.onlinelibrary.wiley.com",
      "url": "https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.29292",
      "authors": "movementdisorders.onlinelibrary.wiley.com",
      "host": "movementdisorders.onlinelibrary.wiley.com",
      "snippet": "by C Nilles · 2023 · Cited by 26 — Copper tests included serum total copper, serum ceruloplasmin (immuno-nephelometric method), and 24-h urinary copper excretion (UCE).",
      "score": 0.534443
    },
    {
      "number": 9,
      "title": "Minimal Criteria to Screen for Wilson Disease: A Delphi ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1155/ijh/5525442",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "These included serum ceruloplasmin and 24-h urine copper testing (values < 10 mg/dL and > 100 μg/24 h, respectively, favor the diagnosis of WD),",
      "score": 0.53385985
    },
    {
      "number": 10,
      "title": "evaluation of the diagnostic criteria for Wilson disease in ...",
      "detail": "aasldpubs.onlinelibrary.wiley.com",
      "url": "https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.23910",
      "authors": "aasldpubs.onlinelibrary.wiley.com",
      "host": "aasldpubs.onlinelibrary.wiley.com",
      "snippet": "by E Nicastro · 2010 · Cited by 267 — For the molecular analysis of the ATP7B gene,. DNA extraction and polymerase chain reaction were carried out with the standard methods by Dr. Georgios.",
      "score": 0.3362008
    },
    {
      "number": 11,
      "title": "Zinc Maintenance Therapy for Wilson Disease: A... : Hepatology Communications",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/hepcomm/fulltext/2019/08000/zinc_maintenance_therapy_for_wilson_disease__a.14.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "The retrospective review by Weiss et al.15 was one of the few that compared the long‐term outcome of treatment with chelation and zinc. Treatment discontinuation due to treatment failure, liver transplantation, or death was seen in 18 of their 88 patients on zinc therapy. Although treatment with che",
      "score": 0.70214266
    },
    {
      "number": 12,
      "title": "Wilson disease: Clinical manifestations,... : Clinical Liver Disease",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/cld/pdf/10.1002/cld.349~wilson-disease-clinical-manifestations-diagnosis-and",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Discontinuation of therapy can lead to the appearance of neurological or psychiatric symptoms or the development of ALF. Monitoring of therapy is critical to detect nonadherence or treatment failure.\n\nThe second phase of treatment, prevention of reaccumulation, or maintenance therapy can be achieved",
      "score": 0.66777676
    },
    {
      "number": 13,
      "title": "Prospective Study to Assess Long‐Term Outcomes of... : JGH Open",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/02045866-202503000-00004",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Clinical studies in healthy volunteers and patients with WD have demonstrated that trientine is effective and generally well tolerated, and may have fewer adverse effects than D‐penicillamine [4][6][13][14][15][16]. A randomized, open‐label, non‐inferiority, Phase 3 trial of trientine in comparison ",
      "score": 0.5697814
    },
    {
      "number": 14,
      "title": "Wilson Disease | Continuum",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/continuum/fulltext/2016/08000/wilson_disease.16.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Liver transplantation typically is necessary in individuals with Wilson disease who develop acute fulminant hepatic failure. Following",
      "score": 0.48235655
    },
    {
      "number": 15,
      "title": "Clinical practice guidelines in Wilson disease - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6531645",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "Three guidelines in Wilson disease (WD) have been issued to date: by the American Association for the Study of Liver Diseases (AASLD) in 2003 with revision in 2008, by the European Association for the Study of the Liver (EASL) in 2012, and most recently by the European Society for Paediatric Gastroe",
      "score": 0.85967577
    },
    {
      "number": 16,
      "title": "Comparative management practices of Wilson disease in Californian and Italian providers - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12487098",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "Currently, there is a scarcity of randomized and high-quality studies to aid clinicians in management and treatment of WD . In addition, the management of WD is challenged by the need of monitoring multiple parameters of copper homeostasis, including 24-hour urinary copper and non-ceruloplasmin copp",
      "score": 0.8215175
    },
    {
      "number": 17,
      "title": "Wilson Disease - GeneReviews® - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK1512",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "Monitoring of individuals under therapy should include routine assessments of treatment efficacy by biochemical testing and clinical evaluation.\n\nAccording to current guidelines (AASLD [Schilsky et al 2022b] and EASL Clinical Practice Guidelines [European Association for Study of Liver 2012]), routi",
      "score": 0.8047902
    },
    {
      "number": 18,
      "title": "Wilson disease: a summary of the updated AASLD Practice Guidance",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10187853",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "“A Multidisciplinary Approach to the Diagnosis and Management of Wilson Disease: 2022 Practice Guidance on Wilson Disease from the American Association for the Study of Liver Diseases” provides a contemporary approach to the diagnosis and management of WD.3 It serves to replace the prior AASLD guida",
      "score": 0.76152116
    },
    {
      "number": 19,
      "title": "Treatment patterns in a real-world cohort of patients with Wilson disease in the United States - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12952460",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "Three treatment guidelines for the treatment of WD have been published (3, 22, 27). WD guidance from the American Association for the Study of Liver Diseases (AASLD, 2022) is the most recent (26). The guidelines of the European Association for the Study of the Liver (EASL) were published in 2012 (22",
      "score": 0.7602419
    },
    {
      "number": 20,
      "title": "Clinical Review - Trientine Hydrochloride (MAR-Trientine) - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK595409",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "### Standards of Therapy\n\nThe treatment of Wilson disease is dependent on the presence of clinically relevant disease or laboratory or histological evidence of aggressive inflammatory hepatic or neurologic injury, and whether the patient is identified before the onset of clinical symptoms.3 Current ",
      "score": 0.6260562
    },
    {
      "number": 21,
      "title": "Clinical practice guidelines in Wilson disease - PubMed - NIH",
      "detail": "pubmed.ncbi.nlm.nih.gov",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31179302",
      "authors": "pubmed.ncbi.nlm.nih.gov",
      "host": "pubmed.ncbi.nlm.nih.gov",
      "snippet": "by CS Palumbo · 2019 · Cited by 130 — The following review aims to compare and contrast the approach to diagnosis and management of WD outlined in each guidance.",
      "score": 0.52627033
    },
    {
      "number": 22,
      "title": "Wilson Disease - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK441990",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "## Deterrence and Patient Education\n\nEarly diagnosis and treatment of Wilson disease is imperative in reducing complications. Patients should be educated about potential unintentional copper intake, including through well water, plumbing systems, and cookware. Maintaining long-term adherence to copp",
      "score": 0.38887385
    },
    {
      "number": 23,
      "title": "Penicillamine - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK513316",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "According to the American Association for the Study of Liver Diseases (AASLD), the adequacy of therapy in Wilson disease is monitored by evaluating clinical and biochemical improvement and measuring 24-hour urinary copper excretion during treatment. Urinary copper excretion is highest immediately af",
      "score": 0.272838
    },
    {
      "number": 24,
      "title": "PROTOCOL TITLE PAGE",
      "detail": "cdn.clinicaltrials.gov",
      "url": "https://cdn.clinicaltrials.gov/large-docs/31/NCT04422431/Prot_000.pdf",
      "authors": "cdn.clinicaltrials.gov",
      "host": "cdn.clinicaltrials.gov",
      "snippet": "Period Day 337. Extension Period Day 337 is the last visit in the Extension Period; treatment with ALXN1840 is complete. Section 5.1, Inclusion Criteria Inclusion criterion #1 for confirmation of diagnosis of Wilson disease changed to Leipzig score ≥ 4 (formerly > 4) and expanded to include historic",
      "score": 0.5142789
    }
  ],
  "publishedAt": "2026-08-24T17:30:16.412006+00:00",
  "updatedAt": "2026-08-24T17:30:16.412006+00:00",
  "readingMinutes": 7,
  "slug": "wilson-disease"
}